

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
25 March 2004 (25.03.2004)

PCT

(10) International Publication Number
WO 2004/024160 A1

527 553
Rec'd PCT/PTO 11 MAR 2005
10/527553



(51) International Patent Classification⁷: **A61K 31/506**,
31/404, 31/165, 31/166, 31/19, 31/4406, A61P 35/02

(21) International Application Number:
PCT/IB2003/004053

(22) International Filing Date:
10 September 2003 (10.09.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/410,286 13 September 2002 (13.09.2002) US
60/411,344 18 September 2002 (18.09.2002) US

(71) Applicants (*for all designated States except US*): **VIRGINIA COMMONWEALTH UNIVERSITY** [US/US];
1101 East Marshall Street, Richmond, VA 23298-0568
(US). **MCGUIRE VA MEDICAL CENTER 111K**
[US/US]; 1201 Broad Rock Boulevard, Richmond, VA
23249 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **DENT, Paul**
[US/US]; 10554 Boscastle Road, Glen Allen, VA 23060

(US). **GRANT, Steven** [US/US]; 206 Desota Drive, Richmond, VA 23298 (US). **KRYSTAL, Geoffrey** [US/US];
9533 Pine Shadow Drive, Richmond, VA 23233 (US).
YU, Chunrong [CN/US]; 901 Pump Road, Apt. 208,
Richmond, VA 23233 (US).

(74) Agent: **HOXIE, Thomas**; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(84) Designated States (*regional*): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMBINATION OF A N-[5-[4-(4-METHYL-PIPERAZINO-METHYL)-BENZOYL-AMIDO]-2-METHYLPHENYL]-4-(3-PYRIDYL)-2-PYRIMIDINE-AMINE AND B) A HISTONE DEACETYLASE INHIBITOR FOR THE TREATMENT OF LEUKEMIA

(57) Abstract: The invention pertains to a combination of a histone deacetylase inhibitor and N-[5-[4-(4methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl]-4-(3-pyridyl)-2-pyrimidine or a pharmaceutically acceptable salt thereof for simultaneous, separate or sequential use for the treatment of leukemia and especially N-15-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2methylphenyl)-4-(3-pyridyl)-2-pyrimidine-resistant leukemia.

WO 2004/024160 A1

